Centro De Inmunologia Molecular

Centro De Inmunologia Molecular (cim)

Gisela Maria González Marinello

Rolando Pérex Rodriguez

Irene Beausoleil Del Gado

Ernesto Chico Véliz

Airama Albisa Novo

Agustín Bienvenido Lage Dávila

Ariadna Cuevas Fiallo

Tania Crobet Ramos

Lisel Viña Rodríguez

Gryssell María Rodríguez Martínez

Loany Calvo González

Tania Crombet Ramos

The present invention concerns the biotechnology sector and more specifically human healthcare. In particular, the present invention describes a vaccine composition for therapeutic use thereof on cancer patients. The vaccine composition described in the present invention has as active principle a chemical conjugate of human recombining Epidermic Growth Factor (hrEGF) and are combining protein P64k. In addition, specific conditions are described for performing a conjugation reaction which produces said chemical conjugate in a controlled and reproducible manner. In another embodiment, the present invention concerns a method for purification of the chemical conjugate which not only provides greater purity for the therapeutic composition, but surprisingly increases the immunogenic activity causing significant increases in the anti-EGF antibody titers in humans. In addition, the present invention provides the methodology for producing a vaccine preparation with more than one type of dose presentation (total milligrams of conjugates/vial). This versatility in the presentation of the vaccine preparation enables the immunization dose per patient to be increased, but without involving an increase in immunization frequency and/or the number of immunization sites. The present invention involves a healthcare method for producing the vaccine for cancer therapy, administered by parenteral means.

Homogeneous vaccine composition comprising a conjugate of EGF and P64K for the treatment of tumors

The present invention is related to the field of immunology and more specifically to cancer immunotherapy, particularly with immunotherapeutic combinations and treatment methods to prevent tumor cell growth and/or to eliminate those cells. The methods described in the present invention are based on the blockade of receptors with protein kinase activity in tyrosine residues (Receptor Tyrosine Kinases, RTK) and of ligands for those receptors. Immunotherapeutic combinations are described that cause the blockade of RTK receptors and/or their ligands, by means of a combination of passive and active immunotherapy. The referenced procedures can be applied to patients in different clinical stages with tumors of epithelial origin that over-express those receptors. The combination of active and passive immunotherapy can be simultaneous or sequential independent of whether the therapeutic procedure will be used in patients with advanced disease or as adjuvant therapy.

Immunotherapeutic combination for the treatment of tumors that over-express receptors with tyrosine kinase activity

Growing community of inventors

Ciudad de la Habana, Cuba

Gisela Maria González Marinello